Highlights from the 2020 CHDI HD Therapeutics Conference are now here! This year’s Postcard covers HTT-lowering therapeutics, including an
Valbenazine approved by U.S. FDA for treatment of chorea in HD
Neurocrine Biosciences, Inc. announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA ® (Valbenazine) capsules for treatment of adults with chorea associated with Huntington disease (HD) in the United States of America. This approval is supported by data from Neurocrine’s two clinical studies conducted in collaboration with the Huntington Study Group (HSG): the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open label extension. Please note that Valbenazine is NOT approved for use in Canada, only in an ongoing capacity to study participants. To read more on these studies and Valbenazine please visit: https://en.hdbuzz.net/348.
We would like to highlight the commitment and courage of the HD community members who participate in clinical trials and their families.